ArticleCancer discovery2020
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation and improving overall immunity.Cell reports. Medicine · 2025Article
- Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.The Journal of clinical investigation · 2025Article
- Review
- Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation.Cancer research · 2025Article
- Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation.Clinical and experimental medicine · 2025Article
- Targeting the PI3K Pathway: Advancements and Achievements in Breast Cancer Therapy.Current pharmaceutical design · 2025Review
- Association of Computed Tomography Scan-Assessed Body Composition with Immune and PI3K/AKT Pathway Proteins in Distinct Breast Cancer Tumor Components.International journal of molecular sciences · 2024Article
- The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review.International journal of molecular sciences · 2024Review
- INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis.The Journal of cell biology · 2024Article
- Article
- [Preliminary Study of the Role of INPP4B in Promoting Colorectal Cancer Metastasis and the Mechanisms Involved].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Role of INPP4B in the proliferation, migration, invasion, and survival of human endometrial cancer cells.Histology and histopathology · 2024Article
- EGFR mutations and abnormal trafficking in cancers.Molecular biology reports · 2024Review
- Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.Journal of translational medicine · 2024Review
- Downregulation of INPP4B is Associated with Poor Prognosis in Epithelial Ovarian Carcinoma.International journal of general medicine · 2024Article
- Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer.Frontiers in oncology · 2024Review
- Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in Bladder Urothelial Carcinoma.Genes · 2023Article
- Phosphoinositides in New Spaces.Cold Spring Harbor perspectives in biology · 2023Review
- The mechanisms of class 1A PI3K and Wnt/β-catenin coupled signaling in breast cancer.Biochemical Society transactions · 2023Review
- Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.Journal of oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Hui LiuDepartment of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. atoker@bidmc.harvard.edu LCantley@med.cornell.edu hliu5@bidmc.harvard.edu.
Marcia N PaddockMeyer Cancer Center, Weill Cornell Medicine, New York, New York.
Haibin WangLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Charles J MurphyMeyer Cancer Center, Weill Cornell Medicine, New York, New York.
Renee C GeckDepartment of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-7812-7675
Adrija J NavarroDepartment of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Gerburg M WulfDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Olivier ElementoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
Volker HauckeLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.ORCID https://orcid.org/0000-0003-3119-6993
Lewis C CantleyMeyer Cancer Center, Weill Cornell Medicine, New York, New York. atoker@bidmc.harvard.edu LCantley@med.cornell.edu hliu5@bidmc.harvard.edu.ORCID https://orcid.org/0000-0002-1298-7653
Alex TokerDepartment of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. atoker@bidmc.harvard.edu LCantley@med.cornell.edu hliu5@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USCornell University · USLeibniz-Forschungsinstitut für Molekulare Pharmakologie · DE
Funding
Role of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2MProject 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI FISCHBACH, CLAUDIA · 2016 to 2020
$10.2MDiscovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in CancerR35CA253097 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Alex Toker · 2020 to 2026
$6.9MNovel regulation of PI3K/Akt to direct targeted breast cancer therapiesR01CA177910 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2013 to 2023
$3.9MOptimization of PI3K-inhibitors to augment the efficacy of microtubule-disrupting chemotherapyR01CA226776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WULF, GERBURG M · 2018 to 2022
$2.1MExploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic BenefitR01CA200671 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TOKER, ALEX · 2016 to 2020
$2.0MRegulation of arginine metabolism as a therapeutic target in breast cancerF31CA213460 · NCI · HARVARD MEDICAL SCHOOL · PI GECK, RENEE CATHERINE · 2017 to 2019
$107kNCI NIH HHS F31 CA213460NCI NIH HHS R01 CA177910NCI NIH HHS R01 CA200671NCI NIH HHS R01 CA226776NCI NIH HHS R35 CA197588NCI NIH HHS R35 CA253097NCI NIH HHS U54 CA210184
Abstract
Inactivation of the tumor suppressor lipid phosphatase INPP4B is common in triple-negative breast cancer (TNBC). We generated a genetically engineered TNBC mouse model deficient in
Indexed as
Disease Models, AnimalGenes, Tumor SuppressorAnimalsAntineoplastic AgentsCells, CulturedHumansMice, TransgenicPhosphatidylinositolsPhosphoric Monoester HydrolasesProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesSignal TransductionTriple Negative Breast NeoplasmsAntineoplastic Agentsphosphatidylinositol-3,4-bisphosphate 4-phosphatasePhosphatidylinositolsphosphoinositide-3,4-bisphosphatePhosphoric Monoester HydrolasesProtein Kinase InhibitorsReceptor Protein-Tyrosine Kinases
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.